In a webcast on Monday, July 15, 2024, Lexeo Therapeutics reported the interim clinical results of their SUNRISE-FA Phase 1/2 clinical trial for the treatment of Friedreich ataxia cardiomyopathy (NCT05445323) and the Weill Cornell Medicine investigator-initiated Phase 1A trial (NCT05302271) (from 8 participants with > 6-months of follow-up):
- Among the participants with elevated left ventricular mass index (LVMI) at baseline, mean reduction in LVMI was 11.4% at 12 months (n=4) and 18.3% at 18 months (n=2)
- Sustained and consistent improvements in other key measures of cardiac status, including left ventricular wall thickness (n=6) and troponin I (n=5), in majority of participants at 12 months
- Increased post-treatment frataxin expression above baseline in those participants from the Lexeo study evaluated via myocardial biopsy to date
- LX2006 was well tolerated with no treatment-related serious adverse events to date
- SUNRISE-FA Phase 1/2 clinical trial is proceeding to Cohort 3; one participant dosed in this cohort to date
Click here to read the full press release: https://ir.lexeotx.com/news-releases/news-release-details/lexeo-therapeutics-announces-positive-interim-phase-12-clinical
Click here to access the webcast recording: https://edge.media-server.com/mmc/p/5tr4f7ek/